%PDF-1.3
%âãÏÓ
1 0 obj
<<
/Type/ExtGState
/OPM 1
>>
endobj
2 0 obj
<<
/SM 0.01
/Type/ExtGState
/FL 1
>>
endobj
3 0 obj
<<
/OP true
/Type/ExtGState
>>
endobj
4 0 obj
<<
/OP false
/Type/ExtGState
>>
endobj
5 0 obj
<<
/Length 7521
>>
stream
/GS0 gs
q
0 0.157 501 700 re
W n
1 g
0 700.157 0 0 re
f
Q
/GS1 gs
/GS2 gs
q
0 J 0 j 10 M []0 d 0.3 w 
0 0 0 1 K
14.173 668.976 m
487.559 668.976 l
S
Q
/GS3 gs
/GS2 gs
q
BT
/F0 1 Tf
9 0 0 9 14.1732 672.0087 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(ARCH SOC ESP OFTALMOL 2007; 82: 765-768)Tj
ET
0 0 0 0 k
14.173 537.3619 473.386 111.771 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
17 0 0 17 67.6508 637.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(OFT)90(ALMOP)74(A)95(T\352A DISTIR)29(OIDEA ASOCIAD)35(A A)]TJ
6.36795 -1.05882 TD
0 Tw
[(HIPO)40(TIR)29(OIDISMO)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
15 0 0 15 49.6859 587.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(D)40(YSTHYR)30(OID OPHTHALMOP)73(A)95(THY ASSOCIA)95(TED WITH)]TJ
8.66959 -1.06667 TD
0 Tw
[(HYPO)40(THYR)29(OIDISM)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 138.3159 543.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(MA)40(CI\347-BOBES C)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8.25 0 0 8.25 224.0074 547.1548 Tm
0 Tr
0 0 0 1 k
0 Tc
(1)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 228.1324 543.5247 Tm
0 Tr
0 0 0 1 k
0 Tc
(,)Tj
0.52499 0 Td
0.025 Tw
[(R)40(ONZ\356N-FERN\347NDEZ A)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8.25 0 0 8.25 359.2914 547.1548 Tm
0 Tr
0 0 0 1 k
0 Tc
(2)Tj
ET
0 0 0 0 k
14.173 31.181 473.386 127.141 re
f
0 J 0 j 10 M []0 d 0.5 w 
0 0 0 1 K
14.173 142.086 m
133.228 142.086 l
S
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 14.1732 131.9149 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(Recibido:)-250(17/5/06. Aceptado: 30/10/07.)]TJ
0 -1.12499 TD
(Secci\227n de Endocrinolog\222a. Departamento de Medicina Interna. Hospital San Agust\222n. Avil\216s. Asturias. Espa\226a.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
6 0 0 6 14.1732 116.555 Tm
0 Tr
0 0 0 1 k
0 Tc
(1)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 21.1732 113.915 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(Doctora en Medicina. )Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
6 0 0 6 14.1732 107.555 Tm
0 Tr
0 0 0 1 k
0 Tc
(2)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 21.1732 104.915 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(Licenciada en Medicina. )Tj
-0.875 -2.25 TD
0 Tw
(Correspondencia:)Tj
0 -1.125 TD
0.025 Tw
(Carmen Maci\207 Bobes)Tj
T*
(Secci\227n de Endocrinolog\222a. Hospital San Agust\222n)Tj
T*
(Camino de Heros, 4)Tj
T*
(33400 Avil\216s (Asturias))Tj
T*
0 Tw
(Espa\226a)Tj
T*
0.025 Tw
(E-mail: cmacb@arrakis.es)Tj
ET
0 0 0 0 k
14.173 197.8 226.772 312.857 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 95.0622 501.7798 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(RESUMEN)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 14.1732 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
0.132 Tw
(Caso cl\222nico:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 80.0027 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
0.132 Tw
(La oftalmopat\222a por enfermedad de)Tj
-5.9845 -1.10454 TD
0.094 Tw
[(Gra)20(v)14(es \(e)15(xoftalmos, inf)20(iltraci\227n muscular y palpe-)]TJ
0 -1.10455 TD
0.16 Tw
(bral\) se asocia casi sistem\207ticamente a hipertiroi-)Tj
T*
0 Tw
(dismo.)Tj
0 -1.10454 TD
(P)Tj
0.54102 0 TD
0.104 Tw
(aciente diagnosticada de hipotiroidismo subcl\222ni)Tj
19.74182 0.00001 TD
(-)Tj
-20.28284 -1.10455 TD
0.01 Tw
(co y tratada adecuadamente con tiroxina oral. Unos)Tj
0 -1.10454 TD
0.06 Tw
[(meses despu\216s desarrolla un e)15(xoftalmos bilateral y)]TJ
0 -1.10455 TD
0.073 Tw
(simult\207neamente presenta anticuerpos s\216ricos anti-)Tj
0 -1.10454 TD
0.008 Tw
(receptor de TSH positi)Tj
9.07905 0 TD
(v)Tj
0.48023 0 TD
(os. Se suspende entonces el)Tj
-9.55928 -1.10455 TD
0.224 Tw
(tratamiento con tiroxina, y se comprueba que el)Tj
T*
0.075 Tw
(hipotiroidismo ha progresado hasta hacerse prima-)Tj
T*
0.129 Tw
(rio. Se establece el diagn\227stico de enfermedad de)Tj
T*
0.025 Tw
[(Gra)20(v)14(es hipotiroidea.)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 14.1732 319.5299 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Discusi\227n:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 66.7626 319.5299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.087 Tw
(El diagn\227stico se bas\227 en la e)Tj
12.28079 0.00001 TD
0 Tw
(xistencia)Tj
-17.06165 -1.10455 TD
0.001 Tc
0.374 Tw
[(de la oftalmopat\222a y los anticuerpos positi)25(v)19(os,)]TJ
0 -1.10454 TD
0 Tc
0.058 Tw
[(ambos espec\222f)20(icos de la enfermedad de Gra)19(v)15(es. La)]TJ
T*
-0.003 Tw
[(coe)15(xistencia de hipotiroidismo es e)15(xcepcional, pero)]TJ
0 -1.10455 TD
0 Tw
(posible.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 14.1732 246.6299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.173 Tw
[(P)10(alabras cla)25(v)10(e:)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 92.0165 246.6299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.173 Tw
(Oftalmopat\222a por enfermedad de)Tj
-7.07666 -1.10454 TD
0.321 Tw
[(Gra)20(v)14(es, hipotiroidismo, anticuerpos anti-receptor)]TJ
0 -1.10455 TD
0.025 Tw
(de tirotropina, tiroxina, terap\216utica.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
9.6 0 0 12 372.053 671.8343 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
[(COMUNICA)55(CI\356N COR)40(T)89(A)]TJ
ET
0 0 0 0 k
260.787 197.8 226.772 312.857 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 339.1405 501.7798 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
[(ABSTRA)55(CT)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 260.7874 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
-0.011 Tw
(Clinical case:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 325.9099 477.4798 Tm
0 Tr
0 0 0 1 k
0 Tc
-0.011 Tw
[(Gra)20(v)14(es\253 ophthalmopath)5(y \(e)15(xophthal-)]TJ
-5.92023 -1.10454 TD
0.049 Tw
[(mos, muscular and e)15(yelid inf)19(iltration\) is associated)]TJ
0 -1.10455 TD
0.025 Tw
[(almost systematically to h)5(yperth)5(yroidism.)]TJ
-0.0001 Tc
(A)'
1.17907 0 Td
0 Tc
0.207 Tw
[(female patient w)10(as diagnosed with subclinical)]TJ
-1.17907 -1.10454 TD
(h)Tj
0.49512 0 TD
0 Tw
(ypoth)Tj
2.27295 0.00001 TD
0.294 Tw
(yroidism and treated with oral th)Tj
14.54309 0 TD
0 Tw
(yroxine.)Tj
-17.31116 -1.10455 TD
0.052 Tw
(Months later she de)Tj
7.98986 0 TD
[(v)15(eloped bilateral e)15(xophthalmos)]TJ
-7.98986 -1.10454 TD
0.308 Tw
[(and w)10(as serum-positi)24(v)15(e for th)5(yrotropin receptor)]TJ
0 -1.10455 TD
0.34 Tw
[(antibodies. Th)5(yroxine treatment w)9(as suspended,)]TJ
0 -1.10454 TD
-0.009 Tw
(and it w)Tj
3.19418 0 TD
(as v)Tj
1.55913 0.00001 TD
[(erif)20(ied that her condition had de)24(v)15(eloped)]TJ
-4.75331 -1.10455 TD
0.11 Tw
[(into primary h)5(ypoth)5(yroidism. A diagnosis of Gra-)]TJ
T*
0.025 Tw
[(v)15(es\325 disease with h)5(ypoth)5(yroidism w)9(as made.)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 260.7874 343.8299 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(Discussion:)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 317.8436 343.8299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.104 Tw
[(The diagnosis w)10(as based on the e)15(xis)-1(-)]TJ
-5.18693 -1.10455 TD
-0.028 Tw
[(tence of ophthalmopath)5(y and positi)25(v)15(e serum antibo)-1(-)]TJ
0 -1.10454 TD
0.224 Tw
(dies, both specif)Tj
6.95446 0.00001 TD
[(ic indicators of Gra)20(v)15(es\325 disease.)]TJ
-6.95446 -1.10455 TD
0.22 Tw
[(The coe)15(xistence of h)5(ypoth)4(yroidism with Gra)20(v)15(es\325)]TJ
0 -1.10454 TD
0.109 Tw
[(disease is e)15(xceptional, b)19(ut possible )]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F0 1 Tf
11 0 0 11 422.8075 295.2299 Tm
0 Tr
0 0 0 1 k
0 Tc
0.109 Tw
[(\(Ar)37(c)15(h Soc Esp)]TJ
-14.7291 -1.10454 TD
0.025 Tw
(Oftalmol 2007; 82: 765-768\).)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
11 0 0 11 260.7874 258.7799 Tm
0 Tr
0 0 0 1 k
0 Tc
0.116 Tw
[(K)25(ey w)10(ords:)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 319.7801 258.7799 Tm
0 Tr
0 0 0 1 k
0 Tc
0.116 Tw
[(Gra)20(v)14(es\253 ophthalmopath)5(y)65(, h)5(ypoth)5(yroi-)]TJ
-5.36297 -1.10454 TD
0.304 Tw
[(dism, th)5(yrotropin receptor antibodies, th)5(yroxine,)]TJ
T*
0 Tw
(therapeutics.)Tj
ET
Q

endstream
endobj
6 0 obj
<<
/Length 9327
>>
stream
/GS0 gs
q
0 0.157 501 700 re
W n
1 g
0 700.157 0 0 re
f
Q
/GS1 gs
q
/GS2 gs
0 0 0 0 k
14.173 29.763 473.386 619.3699 re
f
Q
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 75.4019 640.2562 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
[(INTR)30(ODUCCI\356N)]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 24.9266 615.9562 Tm
0 Tr
0 0 0 1 k
0.0099 Tc
(La)Tj
1.30128 0 Td
0.01 Tc
-0.033 Tw
[(oftalmopat\222a por enfermedad de Gra)20(v)14(es (EG))]TJ
-2.27886 -1.10454 TD
0.116 Tw
[(se caracteriza por un grado v)25(ariable de proptosis)]TJ
T*
0.118 Tw
[(ocular)40(, generalmente bilateral, y signos inf)19(iltrati-)]TJ
T*
0.091 Tw
[(v)20(os de la musculatura e)15(xtr\222nseca del ojo o de los)]TJ
T*
0.047 Tw
(tejidos blandos periorbitarios. Las formas cl\222nica-)Tj
0 -1.10455 TD
0.248 Tw
[(mente e)25(videntes, que cursar\222an con e)14(xoftalmos,)]TJ
T*
0.081 Tw
(quemosis, edemas palpebrales u oftalmoplejia, se)Tj
T*
0.045 Tw
(presentan en un 10-20% de los pacientes con EG,)Tj
T*
0.237 Tw
(aunque las formas sutiles, demostrables en una)Tj
0 -1.10453 TD
0.099 Tw
(tomograf\222a axial computarizada por ejemplo, son)Tj
0 -1.10455 TD
0.079 Tw
[(mucho m\207s pre)25(v)25(alentes (1). De modo infrecuente)]TJ
T*
0.158 Tw
(esta oftalmopat\222a puede aparecer en ausencia de)Tj
T*
0.372 Tw
(hipertiroidismo, bien asociada a normofunci\227n)Tj
T*
0.291 Tw
[(tiroidea o \321e)15(xcepcionalmente\321 a hipofunci\227n)]TJ
T*
0.069 Tw
((2). Presentamos un caso de EG con hipotiroidis-)Tj
T*
0.025 Tw
[(mo y e)15(xoftalmos. )]TJ
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 79.1924 397.5563 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(CASO CL\352NICO)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 24.9266 373.2563 Tm
0 Tr
0 0 0 1 k
0.005 Tc
0.109 Tw
(Mujer de 59 a\226os, sana, no fumadora y asinto-)Tj
-0.97758 -1.10454 TD
0.007 Tw
(m\207tica, remitida desde Atenci\227n Primaria a la con-)Tj
0 -1.10455 TD
0.26 Tw
(sulta de Endocrinolog\222a en agosto de 2003 por)Tj
0 -1.10454 TD
0.133 Tw
(hipotiroidismo subcl\222nico. No presentaba bocio y)Tj
0.0049 Tc
(dos)'
1.77451 0 Td
0.005 Tc
0.116 Tw
(determinaciones recientes de funci\227n tiroidea)Tj
-1.77451 -1.10454 TD
0.01 Tc
0.137 Tw
[(h)5(a)5(b)5<92>5(a)5(n)-392(mostrado ni)24(v)15(eles s\216ricos de tiroxina libre)]TJ
T*
0 Tc
0.035 Tw
[(\()-10(T)-10(4)-10(L)-10(\))-10( )-10(normales y ni)25(v)15(eles de tirotropina (TSH) ele)-1(-)]TJ
0 -1.10453 TD
0.121 Tw
[(v)25(ados: 13,55 y 13,86 mcUI/mL \(v)25(alores normales)]TJ
0 -1.10455 TD
0.01 Tc
0.063 Tw
[<D1>10(V)10(N)10<D1>10(:)-313(0,25-4,22\). Los anticuerpos anti-peroxi-)]TJ
T*
0.085 Tw
[(dasa tiroidea (Ac anti-TPO) eran positi)25(v)19(os a t\222tu-)]TJ
T*
0.253 Tw
(los altos. Con el diagn\227stico de hipotiroidismo)Tj
0 -1.10454 TD
0.039 Tw
(subcl\222nico autoinmunitario sin bocio se inici\227 tra)Tj
20.28285 0 TD
0 Tc
(-)Tj
-20.28285 -1.10455 TD
0.016 Tc
0.369 Tw
(tamiento con 50 mcg/d\222a de tiroxina oral \(1)Tj
0 -1.10454 TD
0.01 Tc
0.093 Tw
(mcg/kg peso\), y se comprob\227 en an\207lisis realiza)Tj
20.28285 0 TD
0 Tc
(-)Tj
-20.28285 -1.10455 TD
0.01 Tc
0.091 Tw
(dos a los 6 y 12 meses que esta dosis de sustitu)Tj
20.28287 0.00001 TD
0 Tc
(-)Tj
-20.28287 -1.10455 TD
0.01 Tc
0.079 Tw
(ci\227n era correcta (TSH normal). En diciembre de)Tj
T*
-0.023 Tw
(2004 la paciente acudi\227 espont\207neamente a la con)Tj
20.28284 0.00001 TD
0 Tc
(-)Tj
-20.28284 -1.10456 TD
0.01 Tc
0.168 Tw
(sulta para comentar que en el \234ltimo mes hab\222a)Tj
0 -1.10454 TD
0.195 Tw
(notado protrusi\227n de los globos oculares, irrita-)Tj
0 -1.10455 TD
-0.009 Tw
(ci\227n conjunti)Tj
5.34535 0.00001 TD
0 Tc
(v)Tj
0.48509 0.00001 TD
0.01 Tc
(al y lagrimeo. A la e)Tj
8.31459 0.00001 TD
(xploraci\227n, rea)Tj
6.1378 0.00001 TD
0 Tc
(-)Tj
-20.28284 -1.10457 TD
0.01 Tc
-0.003 Tw
[(lizada por el Servicio de Oftalmolog\222a, se objeti)25<7697>]TJ
0 -1.1045 TD
0.076 Tw
(un e)Tj
1.795 0 TD
(xoftalmos bilateral moderado y una mot\227rica)Tj
-1.795 -1.1046 TD
0.302 Tw
(ocular normal. Se estableci\227 el diagn\227stico de)Tj
0 -1.1045 TD
0.222 Tw
(oftalmopat\222a de probable origen tiroideo \(no se)Tj
T*
-0.022 Tw
(consideraron indicadas pruebas complementarias\),)Tj
0 -1.1046 TD
0.065 Tw
(se recomend\227 a la paciente tratamiento con l\207gri-)Tj
0 -1.1045 TD
0.054 Tw
[(mas artif)20(iciales, y a la Secci\227n de Endocrinolog\222a)]TJ
T*
0.029 Tw
(la in)Tj
1.7887 0 TD
0 Tc
(v)Tj
0.4951 0 TD
0.01 Tc
0 Tw
(estig)Tj
1.9335 0 TD
0.029 Tw
(aci\227n de una posible EG. Se determina)Tj
16.06556 0.00001 TD
0 Tc
(-)Tj
-20.2828 -1.1046 TD
0.01 Tc
0.194 Tw
[(ron entonces los ni)25(v)15(eles s\216ricos de T4L y TSH)]TJ
22.41947 55.32413 TD
0.109 Tw
(\(normales con tratamiento\), Ac anti-TPO \(positi-)Tj
0 -1.10455 TD
0.044 Tw
[(v)20(os\) y anticuerpos anti-receptor de TSH \(Ac anti-)]TJ
T*
0.152 Tw
[(TSHr\), que fueron igualmente positi)25(v)19(os: 40 U/L)]TJ
T*
0.025 Tw
((VN inferior a 10).)Tj
0.97758 -1.10455 TD
0 Tc
0.245 Tw
(Puesto que estos anticuerpos son virtualmente)Tj
-0.97758 -1.10455 TD
0.067 Tw
(patognom\227nicos de la EG, y puesto que la normo-)Tj
0 -1.10454 TD
0.078 Tw
(funci\227n tiroidea en esta enfermedad es menos rara)Tj
0 -1.10453 TD
0.01 Tw
(que la hipofunci\227n, se suspendi\227 el tratamiento con)Tj
0 -1.10455 TD
0.22 Tw
(tiroxina para comprobar el estatus de la funci\227n)Tj
T*
0.206 Tw
(tiroidea intr\222nseca \(que no puede establecerse en)Tj
T*
0.078 Tw
[(presencia de tratamiento\). T)35(ras dos meses sin tiro-)]TJ
T*
0.037 Tw
(xina oral la T4L era de 0,47 ng/dL (VN: 0,7-1,7) y)Tj
T*
-0.005 Tc
-0.001 Tw
(la TSH de 54,01, por lo que la paciente fue diagnos-)Tj
0 -1.10454 TD
0.057 Tw
(ticada de hipotiroidismo primario franco en el seno)Tj
T*
0.099 Tw
[(de una EG y se reintrodujo tratamiento sustituti)25(v)19(o.)]TJ
T*
0.029 Tw
[(Hasta la actualidad (abril de 2006) el e)15(xoftalmos ha)]TJ
T*
0.325 Tw
(permanecido sin cambios \(re)Tj
12.33661 0.00001 TD
(visiones anuales en)Tj
-12.33661 -1.10455 TD
0.259 Tw
(Oftalmolog\222a\), y la funci\227n tiroidea \321con trata)Tj
20.28285 0.00001 TD
0 Tc
(-)Tj
-20.28285 -1.10455 TD
-0.005 Tc
0.025 Tw
(miento\321 es normal. )Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 338.0646 384.6219 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(DISCUSI\356N)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 271.5408 360.322 Tm
0 Tr
0 0 0 1 k
0 Tc
0.194 Tw
[(Al diagn\227stico de EG se puede lle)15(g)5(ar por dos)]TJ
-0.97758 -1.10454 TD
0.078 Tw
(v\222as: la que parte de un paciente con hipertiroidis)Tj
20.28283 0.00001 TD
(-)Tj
-20.28283 -1.10454 TD
0.036 Tw
(mo, que consulta en Endocrinolog\222a, y la que parte)Tj
0 -1.10455 TD
-0.007 Tw
[(de un paciente con oftalmopat\222a sugesti)25(v)25(a, que con-)]TJ
0 -1.10454 TD
0.002 Tw
(sulta en Oftalmolog\222a. En el primer caso, la demos-)Tj
T*
0.194 Tw
(traci\227n de unos Ac anti-TSHr positi)Tj
15.24817 0 TD
(v)Tj
0.48022 0 TD
(os en suero)Tj
-15.72839 -1.10455 TD
0 Tw
(conf)Tj
1.75684 0 TD
0.23 Tw
(irma el diagn\227stico. T)Tj
9.38593 0.00001 TD
(ambi\216n lo conf)Tj
6.4386 0 TD
(irma la)Tj
-17.58136 -1.10455 TD
0.014 Tw
[(e)15(xistencia de la oftalmopat\222a, pero \216sta es poco fre-)]TJ
T*
0.023 Tw
(cuente y no suele aparecer en ausencia de anticuer-)Tj
T*
0.051 Tw
[(pos. Cabe, por \234ltimo, un diagn\227stico de e)15(xclusi\227n)]TJ
0 -1.10454 TD
-0.002 Tw
(en sujetos hipertiroideos sin anticuerpos y sin oftal)Tj
20.28283 0 TD
(-)Tj
-20.28283 -1.10455 TD
0.081 Tw
(mopat\222a, pero sin bocio o con un bocio difuso \(no)Tj
0 -1.10454 TD
0.025 Tw
(nodular\) \(3\).)Tj
0.97758 -1.10455 TD
0.013 Tw
(En los casos en los que el s\222ntoma-gu\222a inicial es)Tj
-0.97758 -1.10455 TD
0.066 Tw
[(la oftalmopat\222a, se debe in)40(v)15(estig)4(ar siempre el esta-)]TJ
T*
0.068 Tw
(do de la funci\227n tiroidea. Si se comprueba hiperti-)Tj
0 -1.10454 TD
0.015 Tw
[(roidismo la enfermedad de Gra)20(v)15(es es se)14(gura. Si no,)]TJ
T*
-0.03 Tw
(el diagn\227stico requiere la positi)Tj
12.40558 0.00001 TD
(vidad de los Ac anti-)Tj
-12.40558 -1.10455 TD
0.024 Tw
[(TSHr)40(, en ausencia de los cuales \(aunque puede tra-)]TJ
0 -1.10454 TD
0.076 Tw
[(tarse de una limitaci\227n de la t\216cnica\) resulta a)20(v)15(en)-1(-)]TJ
T*
0.07 Tw
(turado establecer con certeza la EG. En ocasiones,)Tj
0 -1.10455 TD
0.033 Tw
(con el paso del tiempo, el paciente acaba sufriendo)Tj
0 -1.10454 TD
0.108 Tw
[(un hipertiroidismo o se acaban positi)25(vizando anti-)]TJ
0 -1.10455 TD
0.025 Tw
[(cuerpos pre)25(viamente ne)15(g)4(ati)25(v)20(os (4).)]TJ
0.97758 -1.10455 TD
0.193 Tw
[(Es posible la coe)15(xistencia de una oftalmopat\222a)]TJ
-0.97758 -1.10454 TD
0 Tw
(sugesti)Tj
2.75244 0.00001 TD
0.041 Tw
[(v)25(a de EG y unos Ac anti-TSHr positi)25(v)20(os \(es)]TJ
-2.75244 -1.10456 TD
0.245 Tw
[(decir)40(, de una EG\), junto con un hipotiroidismo,)]TJ
0 -1.10455 TD
0.197 Tw
(situaci\227n que algunos autores denominan \307enfer-)Tj
ET
0 0 0 0 k
14.173 7.5279 29.435 12.314 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
12 0 0 12 14.1732 11.6477 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(766)Tj
ET
0 0 0 0 k
137.36 10.6629 228.784 9.179 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 170.0444 14.3792 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(ARCH SOC ESP OFTALMOL 2007; 82: 765-768 )Tj
ET
0 0 0 0 k
14.173 668.976 473.386 9.178 re
f
BT
/F2 1 Tf
8 0 0 8 14.1732 672.6915 Tm
0 0 0 1 k
(MACI\347-BOBES C, et al.)Tj
ET
0 J 0 j 10 M []0 d 0.3 w 
0 0 0 1 K
14.173 668.976 m
487.559 668.976 l
S
Q

endstream
endobj
7 0 obj
<<
/Length 4082
>>
stream
/GS0 gs
q
0 0.157 501 700 re
W n
1 g
0 700.157 0 0 re
f
Q
/GS1 gs
q
/GS2 gs
0 0 0 0 k
14.173 408.1469 473.386 240.986 re
f
Q
/GS2 gs
q
BT
/F2 1 Tf
11 0 0 11 14.1732 641.6219 Tm
0 Tr
0 0 0 1 k
0 Tc
-0.001 Tw
[(medad de Gra)20(v)15(es hipotiroidea\310, por analog\222a con la)]TJ
0 -1.10455 TD
0.01 Tw
[(EG eutiroidea. En un estudio realizado en Sing)5(apur)]TJ
T*
0.029 Tw
(sobre m\207s de 1000 pacientes con este tipo de oftal-)Tj
T*
0.199 Tw
(mopat\222a se comprob\227 que s\227lo un 1,9% no eran)Tj
T*
0.043 Tw
(hipertiroideos, y de ellos s\227lo un 0,2% eran hipoti-)Tj
T*
-0.002 Tw
(roideos (2). Se han publicado casos aislados de esta)Tj
0 -1.10454 TD
-0.026 Tw
[(v)25(ariante de la EG, en ocasiones con formas de oftal-)]TJ
0 -1.10453 TD
0.01 Tw
[(mopat\222a se)25(v)15(era, con hipotiroidismos muy marcados)]TJ
0 -1.10455 TD
-0.0001 Tc
(y)Tj
0.94846 0 Td
0 Tc
0.199 Tw
(con t\222tulos muy altos de Ac anti-TSHr (5). El)Tj
-0.94846 -1.10455 TD
0.068 Tw
[(mecanismo f)20(isiopatol\227gico implicado parece ser la)]TJ
T*
0.109 Tw
(capacidad de inhibici\227n de la funci\227n tiroidea por)Tj
T*
0.029 Tw
(parte de alg\234n tipo de Ac anti-TSHr: la mayor\222a de)Tj
T*
0.106 Tw
[(estos anticuerpos son estimulantes del receptor)40(, lo)]TJ
0 -1.10454 TD
0.056 Tw
[(cual se traduce en hiperfunci\227n y bocio, pero e)15(xis-)]TJ
T*
0.006 Tw
(tir\222a un subgrupo no estimulante \320que bloquear\222a el)Tj
T*
-0.031 Tw
(receptor (4). Con los m\216todos anal\222ticos disponibles)Tj
T*
0.002 Tw
(actualmente en la cl\222nica habitual no es posible dis)Tj
20.28284 0.00001 TD
(-)Tj
-20.28284 -1.10455 TD
0.025 Tw
(tinguir ambos subgrupos.)Tj
0.97758 -1.10454 TD
0.281 Tw
[(En resumen la EG con hipotiroidismo e)15(xiste,)]TJ
-0.97758 -1.10455 TD
0.086 Tw
[(aunque es e)15(xcepcional, y a su diagn\227stico se lle)15(g)5(a)]TJ
22.41947 20.98635 TD
0.092 Tw
(siempre a partir del estudio de funci\227n tiroidea de)Tj
0 -1.10455 TD
0.025 Tw
(un paciente con oftalmopat\222a.)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F1 1 Tf
13 0 0 13 325.4232 591.1719 Tm
0 Tr
0 0 0 1 k
0 Tc
0 Tw
(BIBLIOGRAF\352A)Tj
ET
Q
/GS3 gs
/GS2 gs
q
BT
/F0 1 Tf
9 0 0 9 265.2874 571.1718 Tm
0 Tr
0 0 0 1 k
0 Tc
0.16 Tw
[(1.)-640(P\216rez Moreiras JV, Coloma Bockos JE, Prada S\207nchez)]TJ
1.38977 -1.11111 TD
0.234 Tw
(MC. Orbitopat\222a tiroidea \(fisiopatolog\222a, diagn\227stico y)Tj
T*
0.025 Tw
(tratamiento\). Arch Soc Esp Oftalmol 2003; 78: 407-431.)Tj
-1.38977 -1.11112 TD
0.164 Tw
[(2.)-640(Khoo DH, Eng PH, Ho SC, Tai ES, Morgenthaler NG,)]TJ
1.38977 -1.11111 TD
0.098 Tw
(Seah LL et al. Graves\253ophthalmopathy in the absence of)Tj
T*
-0.021 Tw
(elevated free thyroxine and triiodothyronine levels: preva-)Tj
T*
0.089 Tw
(lence, natural history, and thyrotropin receptor antibody)Tj
T*
0.025 Tw
(levels. Thyroid 2000; 10: 1093-1100.)Tj
-1.38977 -1.11112 TD
0.024 Tw
[(3.)-640(Teissier MP, Lopez S. Orbitopathie dysthyro\225dienne: phy-)]TJ
1.38977 -1.11111 TD
0.052 Tw
(siopathologie, \216quilibre hormonal. J Fr Ophtalmol 2004;)Tj
T*
0.025 Tw
(27: 806-809.)Tj
-1.38977 -1.11111 TD
-0.005 Tw
[(4.)-640(Kazuo K, Fujikado T, Ohmi G, Hosohata J, Tano Y. Value)]TJ
1.38977 -1.11111 TD
0.018 Tw
(of thyroid stimulating antibody in the diagnosis of thyroid)Tj
0 -1.11112 TD
0.269 Tw
(associated ophthalmopathy of euthyroid patients. Br J)Tj
0 -1.11111 TD
0.025 Tw
(Ophthalmol 1997; 81: 1080-1083.)Tj
-1.38977 -1.11111 TD
(5.)Tj
1.38977 0 TD
0.093 Tw
(Jorge Z, Nobre EL, Santana A, Castro JJ. Doen\215a auto-)Tj
0 -1.11112 TD
0.025 Tw
(imune da tiroideia. Acta Med Port 2005; 18: 88-92.)Tj
ET
0 0 0 0 k
461.93 8.5039 25.629 11.338 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
12 0 0 12 469.559 11.6477 Tm
0 Tr
0 0 0 1 k
0 Tc
(767)Tj
ET
0 0 0 0 k
137.614 10.57 228.784 9.178 re
f
Q
/GS3 gs
/GS2 gs
q
BT
/F2 1 Tf
8 0 0 8 170.2989 14.2856 Tm
0 Tr
0 0 0 1 k
0 Tc
0.025 Tw
(ARCH SOC ESP OFTALMOL 2007; 82: 765-768 )Tj
ET
0 0 0 0 k
14.173 668.976 473.386 9.178 re
f
BT
/F2 1 Tf
8 0 0 8 390.2957 672.6915 Tm
0 0 0 1 k
(Oftalmopat\222a e hipotiroidismo)Tj
ET
0 J 0 j 10 M []0 d 0.3 w 
0 0 0 1 K
14.173 668.976 m
487.559 668.976 l
S
Q

endstream
endobj
8 0 obj
<<
/Nums[0<</S/D/St 765>>]
>>
endobj
9 0 obj
<<
/BaseEncoding/MacRomanEncoding
/Type/Encoding
/Differences[32/space 40/parenleft/parenright 44/comma/hyphen/period 48/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 65/A/B/C/D/E/F/G/H 74/J/K/L/M/N/O/P 82/R/S/T 86/V 89/Y/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v 120/x/y/z 135/aacute 141/ccedilla/eacute 146/iacute 149/idieresis 151/oacute 171/acute]
>>
endobj
10 0 obj
<<
/Subtype/Type1C
/Length 8239
/Length1 8239
>>
stream
  FXYGCU+Times-Italic   @ø øøøøû=ûmú†ú
 ‹‹
 ‹‹  7  3  Æ»  ÿ ·ÃÈ003.001Copyright (c) 1985, 1987, 1989, 1990, 1993, 1997, 1998, 1999 Adobe Systems Incorporated.  All Rights Reserved.Times is a trademark of Linotype-Hell AG and/or its subsidiaries.Times ItalicTimes  F  " 3 $ )  4 0 & 1 ' 5 - .          	 S D I P T Q G U B M N 
   Ï F [ J + 7  # L E È O C Ó H Ø Z   , % / ( W } Y V  Õ R K : ; Î H   xYèëp¿NÆG™î}ÔUŸ'pŞ)D‰ğ	<	Ñ

•*©!©ù®ìgß9—üO¥Îkô8º1šQ·/œßvßWÇ4^
‘üyìmÜ¥ü$d‹›÷f¯ø*wX÷ûøûû<÷<èøù0û¶üˆô9û ‚ˆe‚{÷O›]~¥¡‘˜™¦Ä÷÷pŸû}‹}‹Šcq…W‡{÷Š›Q…–Ñ-øÊûoü*÷)÷—Œ·û—d‹›ÿ6€ ÿ "€ ÷š©{›øwôØøË›U{®~®.÷‰÷#¦ÁÑÚ÷$û@‹gûŒ{º…£‰d‚hˆ€ûüNyL‰X‚{÷ˆ›U’}±“‹—¸Ã÷eÌ†÷ûØ÷(èû—øç’•¸ÄÉt5@f=û$pƒŒsœy¸øï¯Í÷ù øe°÷[v†…ntN£CûyûEûqûUû\÷&E÷÷&äô·°z™[\EDû‹ûTŞ÷÷'ñ÷†÷\÷#”ûoÓ‹›÷Êµ÷¡›ƒù›ù“ù!û‹{¶†¦ˆhy†s…w]û8û±Á÷WÍ»®›û¥{½‡¦†iy†s…wûüNzM|ˆZ‚{÷Š›_‘p­‘Œ“”Í÷ˆ÷±Jû€yKf‡]…{÷¥›]k¯‘Œ“”÷øuœÊ›¼”ü$û*y®€vù¬¾Éã÷â¼øhøh³÷[ty‚ƒtw‘’x‘ys‘^.<H*J€÷û'¬h°lKYh9-1SÚä“ŒŒ“w|iûs¼˜’Ÿ§­¾gĞ÷ÑóéÍv²/ç4à£ºÎ¾¬Â÷"RŒÓy¬øş¬ÇôøAôùOø;÷<ûÖûûGûxûnûqûR÷Tà÷t÷X÷„÷]üªû†÷ï÷Ö÷Zê¯E0û+ûãû_û‹÷#¢d‹¬÷»¬÷—¬{›øÜèùù!ü…Ø{¾‡¥†h€ƒcˆûüNzM|ˆZ‚{øÉ÷6{“D(`eûU‹q`ª—Ë÷{÷7†‹‹Z{ˆ{‡|Ÿ†Ï÷|yu‚x‚}ul…‚û5‰èÍ÷}‘Ÿ‘Ó‹÷2¦|MŠ~Š{ ‰d‹›÷µ°÷­©{›øŠòØ÷&ùµ†¨ˆf}c„tû
ü=yK~‰Xƒ{÷‰›W’{­œ‹‹—·À÷U¡†™ˆÑ‹÷\Ä÷Õè÷+û;Œ_ûŒ÷DQ—‘›©÷©aAû9û‹B~wd‹›÷É¯÷—¬{›øçØùù!ü†{¿‡¤‰fy„m‡}ûüNyK~‰Xƒ{÷›ia³–—‘¡É÷sŠ³‰¼‹œ¬ˆ_v†tˆ}œ†×÷~y]1‰‹û<ˆèÍ÷}’¢–Ê‹÷(¯~L}‰}Š} ‰-‹›øî®øÓ™ùù!ü¨aû.‡Å÷½‹÷‹û$ü¤yI`‡^‡{÷¶›@|Œ´™š“§÷ø†ÂË³{D€Š~‰|œ‰-‹¯øí›ƒøËø'ù!û¥{½‡¦†iy†s…wûüNzM|ˆZ‚{ø‘Å÷Gw‘Iû&:ˆû‹WY‹®‹Œ”±÷øOÍ»®÷K‹›ù›y÷ûúĞùıù!û;ûáü}ˆTø}ûI{ÂŠzv‚€l€cà!üjûw„^„{÷Z›kd³’£÷ø;Çü¬œøø½ûüb}WtzK…{÷¥›Rw°Ÿ‘ ÷øOœÊ—À”û*‹×ø£Ôøáø$÷gz{pIûR÷T÷T÷÷¤¸‹ÎÖSç!rû‡û0U „™¤±Ğå‹Ø¹OMj‡Qû û)ûfûtz÷÷½÷û*„§ù§«Ú÷ÇÚ÷÷0ìÓø÷)á‹%mûC5ûÔûkT÷ø÷¢íp÷,ûûû:ûbû¢#Ä$ó÷<÷÷÷Zû*˜vøíÔ•Öøb°ø­ù$…•Ğü:û™‚­³¦«Ó‹÷rˆüüêÑûÑ v÷Ş÷‹wñË{÷°¯ûÄ§ÔÊÎ¶r¨iƒa†a_¸Š‹ifTfw~È÷FøN ®›±«r¤lmrsjd­| û*„¡ù¢©Ï³Ù÷-ÖxÏô©÷1m û÷Gø÷ÛäáÙcÈ@ÖôÂ÷¯ì÷û ¬I-4Z$W¥\ÈJôs„û?Xû%Ïˆ÷÷Â¥“øì'¤qJ+=aUô5VÇÚ÷
øÎ±·ËÜ¥F[8PoTq,á‹ª¥ûÑ•v‹÷÷z÷‹w½÷€÷˜õ€ ­›±X«q¤nlrql˜e­{¡¤î÷é ®›±«r¤lmrsjd­| û*„¥øœz¯÷s›©×÷äÜøœùBûÅxûMûûbû8îVÜ÷>Ü÷=ğ¼÷"&µG{|‰‡|Ü|ˆ}†}„‡£½÷÷=÷D¢ûŸû—×µ[91Uû@û)‹÷¥›•÷‚÷û*„µøÄÒ÷òĞ÷‚øç÷z¢Òû”#ûn|÷ròuû-4Bû)UrÂ‹^xvno©oÓ÷Wö÷.÷÷1Óû¥ûÑ v÷TÊ¼÷}÷®÷“ûo}L÷pûÑ vù"w®wµĞ°÷3ûC[÷‹ãÎÊœ÷³÷Ğ»÷¾Á»½°~šûJû/=û0‹û9K‹û&îû8û™ v÷èğJÌd—¸øÈ÷´÷™¸±Ó¨š“Ç÷ªÈ£|g‹¶–¯‹¿­rštL?û	Ijƒw‰¼÷[ˆ˜^„P~X„z–––ª{}‚…if:û¸ûb€¯ø4v©á÷râ÷òõcg\bONm¸ØëĞ÷E÷Ÿ†|z|…‹qtš}¤¤¡§ªr½7û(ûû-û!ûŞrÌôÅÖ«¤û*‚ºzvø¾ÿ Ç€ ÿ € ¡w÷´ÚÙ´øe÷	[eslwƒƒ’—j Ü÷”‹®Ì]’u1%û.Yl‰÷
øK†rWV‚W…{¥Œ¬Š“~‹|{R€aûü‰Ö¬÷šÂ¸ÏŸ§ß÷½‹›‹˜‹z´~9û³‹qp˜x«Í¶É¿¯û*•vøXv¦ß÷¥ß÷ÕøMû&û(û5û'8¸Nõ÷-÷÷I÷Ílİû„v»¡_W <ûcûYm¯Ä÷
æ÷[÷û™•v÷÷1÷…¢÷Ô¹×¥›œ¯÷&wû3›\–‘•™œ¨³x‹©Ãè¤÷àûä‹Ê¼«”¡Ì£QR®›œŸ÷}¬ƒ†…zœmwœ‹^!};l>÷+‹Ij{[S:{ç·„û*ûaš÷Gø¶‹w@÷!°™÷šåîø÷Íû1ûNûrr–¥²³÷¤ËÏ¥Å¹ºÌŒQpû×å¢Œ zv%üpûkƒ…pV{÷ašqe‹«Ÿ§÷”­¢Ÿ†¤÷÷4÷:÷/ÓmÆ29RBhs‰¦èŒŒ‹ˆŒ‰Şû/uüûNvøï«÷x¡û'×ø4Ú®ø å3ü8ƒcqûK‹„““–”‹‹œ£s˜}‰g‰‹eˆ]‘´~ª÷	Ã÷5÷§Ó÷Ô÷‘«û ¾”©÷Eİ˜•‡ƒ€‹‹u€‘p«¢ŸŸŸ{¸CûYû96q/ü€¼÷ú«°Ü:÷—Ğ÷¼ø@;§ò‹Œ‹‰‡‡ƒˆ„†‡àoh[^jzz‚o„…‚‰ˆŠˆ‹‡‹‰Œ‰‹‰ÕCû§‡{xN‹|m§Ÿ¿²·Ø¾~’rkh\w‹€†“”‹Œã÷áßû*€¼[¾ø!wŒ¡œß÷XÔ†œlød÷_^wr|ƒ…‘’ªç÷é—„šN„ˆˆ_‰§ˆj¥`ûû-ûOû'n2ïœÇÀ©÷Ş‰{N†u‹tz‹qµ¶­¯ÕÇü”åå÷p÷	š¨§x[))ûl!œpjÀü€¶øô›¡w´ØĞ÷x÷LZvor|‹™‘–“¦”°÷+ø×†ĞWW‚W…{™¤¨ˆuvû%ü‹voi·É²»Ø¾Ó‚ºzvø¿\›÷öØß×Ú¬ùE÷	\eqkxˆœj™Ü÷ ‹­³t¦gI:3ûE‰™³¢Ş‹™µv¢e7$û/Zm‰Ã÷\ˆZV€VU{¼š‰uu9û®{IÖ°÷ŸÍ³Çj³¦×ğ¸”˜‹pxFûŠq*Ö¨÷œÊ»×ª¼Óã´‹—‹”ƒ‹|¬w=û«‹p}‹hµÃ½Ã¾¯’ûÑ vù1w÷pĞ¨ûH÷(÷÷÷:÷Q÷p÷C÷	x†¥T¢(‹ 3{ûbû^ûQN_]ü$•v‹÷¦÷ İ€ ®œ°`ªq¥mmrrk e­{ û*‹šøö˜±w¼÷ü¼÷«š}`n§›˜°Ÿ÷#ø›•–‹“Šˆƒûmƒ\|Ä”‹¨‹‹kƒ‡}ˆ€ûü€~^cˆP…ûb€¸ø¢÷swªâ÷xÍ÷,÷ä°ÏØÁ¤•xvƒ†ûûba÷s(bYaiUaW¢ÏŸŸ §÷6¢éÜ‹Ú·l£Xû!û2û<û#L«=ôïæç›–Óø‹–’‘’š|œv€ƒ‡……û6û4®ûb€¸ø¢ªâ÷xÍ÷,÷ä°ÏØÁ¤•xvƒ†ûûba÷s(bYaiUaW¢ÏŸŸ §÷6¢éÜ‹Ú·l£Xû!û2û<û#L«=ôïæç›–û™OvívøÇ÷ºĞÜ÷ÉÃ¡ ±÷&ûÊü”‚˜–š’œ‹ÑÓ5‹Ö¾¶°±«r‚t}zu™€‹€~{ˆx‹¬qWÎzI™÷¶÷ì–û°lûü€ºø ›¤w÷õ¼Ö¶ì¼÷r÷Qbnw‚„“’——³™ã÷ÖˆÜd„8{e‰{Â“†vo<ûŒ‹\y‹_ºÃ·ÂÆ²¨ø„¡z¬jstxhh¢z¤¬›ªŸûbyªù›…èøù!û’{¸‡«ˆhwƒo‡|ûüe…w‚ii‹r™¤•Œ”‹‘¤u¡qnztlNÇpÀ÷²óõ¨òøË˜¾“dvù#›øÉ÷ùDù!ûN{‰·‡no`A‚{û^ûñ†JøHŠ‘‹‹´©º›û…{Ã„†Ÿûàüœø	øû‘•©ª‹ü$û÷zÒËûÄ§ÔÊÎ¶r¨iƒa†a_¸Š‹ifTfw~d‹©÷Áª÷™©{›÷cõ÷
÷ WğÒƒ÷®Ô÷÷É÷íE©V¢ÚéÙ¶å÷+­#û–{ºˆ©ˆfz†u…tûüNzM|ˆZ‚÷GÆ¿÷AšËÜÏŠ¹Š¤{©x£h‹X‹(R<û!‹Únj’±ê÷"øœš˜ÂÖ°gGûûy.€€Œ‹ûb€¿wvø0›÷h›¡w™øSû÷´ø2÷Ynyuqx¹÷?Cj÷÷±©¼›ûK{¦§‹xlû+T`‰÷øY†tWW‚W…{™¤¨ˆu‰uuA‚gûüwÖ»÷Hµ«´•m±3—t©Ptª‹·‹¨°±Óû*~ÀX»ø¢÷^œwšâ÷M×„šu÷7°N‹Äœæê÷l÷º‹_tû)ûR,®÷ÀÕ[awtwƒ’š›÷ø>¶÷B†uX€X„X†zÂŠ’†t}„rƒo`û3‰‰‡¡„¬S‹ûû>ûKû+W IŞv½Ãœ÷Ó‰ƒh‡t‹tv“r²¬ÌºÎ¶û*€¼[¾ø!wŒ¡÷swœß÷XÔ†œnød÷_^wr|ƒ…‘’ªç÷é—„N„ˆˆ_‰§ˆj¥`ûû-ûOû'n2ïÇÀ©÷Ş‰{N†u‹tz‹qµ¶­¯ÕÇü”åå÷p÷	¨§x[))ûl!pjÀøø–’‘’š|œv€ƒ‡……û6û4®û*‚ºzvø¾\›÷³ÖŠÜ¨ø`÷	\frkw‰}šd©Û÷‹‹¶µt£]8/ûA\‰Ë÷eˆXU€UU{Á•€|vHû~lûÖ´÷˜¶¹ĞdÃ¯Êá»‘}y¨cAûˆ‹snm¹Á®¹Î½û*€¢ø¼÷^œw¢á÷«àìø÷Ç7,ûgû\‹¥’ôë÷†÷Ê•Ulûª÷äÅŠ’†t}‚r„oûü‰‡uØlÀ÷-÷;÷A÷2ÔZ»E1L.Wj‰ŒÜ­÷¹÷N¡İ†ìWX„Y…ü€ºø ›¤w÷‡w¼Ö¸÷r÷Qbnw‚„“’——³™ã÷ÖˆØd„8{e‰{Â“†vo<ûŒ‹\y‹_ºÃ·ÂÆ²òø…–’‘’š|œv€ƒ‡……û6û4®û*ûb¡÷øv÷k²™¡“Â¬Ù÷+ÇjÚşølø)N„‚””zŞ”yr”b9ûQûF¶s¯{it`nlxš—‚7TjuRTÀS÷÷ÙÈà÷ûi{‹À˜¡¦™˜™‡‹˜ıãêİÕŸˆŸ…½Şû'ü[YZ^1|û è¢‹¦´®­¦‘“ìf‚‚¯z^İ¦øL8Y+I^z¬¸Î·ñØµšndû*•vøXv÷ˆw¦ß÷¥ß÷ÕøMû&û(û5û'8¸Nõ÷-÷÷I÷Ílİû„v»¡_W <ûcûYm¯Ä÷
æ÷[÷÷0÷H–’‘’š|œv€ƒ‡……û6û4®ûbûbÂTŞø£˜£wø³¨šø$—’ŒšÄ˜`0¦œUµûCepaZrnci~‚{Xy~§‹mvzzv˜a¶ˆ“÷÷¬øf÷¯w¥fq€v}]Á–‹bV<û`Ew÷~ÖP÷F~‹y={ƒ[û*„±øïµ÷ÙÛpâĞ÷FøËŸš®ºÊ±¼sHû û_'}Œ{’Œ“‹’‹àãÖaûû-iiSjÇ‹]fyv^Â}Æ÷Mæ÷"÷÷F©q—Ğô²½®×ŞCµAR@_Orû* v÷FÊøGwŒør÷©÷…ûh÷Ä÷ÒÛûÖ,÷øGbü5üCwH÷šZûFÚ¹÷Dïœ‹›ÿB€ ¯ÿ€ ›’ù_ùfù!ûr{Â†‘ˆzr?KG[û$&…Œ¾÷PÍ½¬›û¥{½‡¦†iy†s…wûüNzL‰V‚{÷Œ›V‘x±™—”«Ç÷o“Š÷ûZ—v¥[‹ruv‰U…{÷§›P‘Œo¼ûB÷Ã÷À÷v’®¥¬Ó‹©øå©{›÷cõ÷¨÷¸÷ù¾‡¥†iwƒlˆ€ûüNzM|ˆZ‚{÷‘÷º÷5÷M÷^ØôM÷5ûzûª÷KP™šÄ÷E­û&NjûÈûÏ\s‘¬›˜·”¬œ‘vš›ù›w÷ø~÷xùkù!û[{Â‡šdz„x‡}&üˆûbøƒû5{»ˆ {œfûü5fû€Tƒ{÷Z›nb³“’¥÷ø4¨÷xü´÷$ø‹­÷™Ì™Óy°÷°›÷Í­¿÷ùXù*|}}wd‹qM­‹6ûjûSûYûy`¨ûk÷œÔé¡³Ë¼÷OœË¦À›û{Á†£ˆn{gûBnttnr€Xû>k÷Ù÷8í÷‹÷]Òïjû”ˆûbvø:—¤w÷Ò÷<¾Ø ø'Œ•“‹“¼u=™•Q˜û6Cz‹~”šŸÒÍ¸¬®÷)÷Fç°s¥jw{}|Uµ–‹dY;ûRPlk„÷…İm÷†ŠŒƒ‰†Z}€BûÑ vù,w÷H÷søøì–’‘’š|œv€ƒ‡……û6û4®ûb€ÂTÅQØ÷ÂÔSÃf°pønŠø&÷mpwfvw„¤›‡…¤i÷‹Ï÷¨’¡’z‹££•Š£u—xW\N9W€Âyã|‹u‹kIs‚pF|«“™”‹¦}l”Œ†­û‚û1qiz*yy‹uuy{Šs›x¬ª—–œ­°µÁ»Í©ûV˜š}¨¢¨‹÷Òû*€ÀXº÷ş™w¨wµØ÷>ÙVøa÷	_hohx€Š–š˜·‘ŸÚ÷¿Ad uLZAWiL-`z†˜—‹Œæ÷ÿˆ¦YY‚Y…}´‹np?û‹__|¯åÕ÷÷ÏNt9w7y|f¸½¥¥æÊû*v÷Š¹vø¥Ğã÷˜Ö¼¢z÷Á¯÷<÷}÷^÷(;Õ$û	ûûûÜûÍHà··¥³‰€`ûûYûJl÷ø/è»÷%÷î‹û dp{%rd`oSzl'‡ô«ü€ºø ›¤wâí¼ÖEíñíº÷r÷Qbnw‚„“’——³™ã÷ÖˆÚd„8{e‰{Â“†vo<ûŒ‹\y‹_ºÃ·ÂÆ²¶ûø‹wm|jn¡v¦¦¡¡¦¬l›z÷\wm|jn¡v¦¦¡¡¦¬l›zû*ûe÷HÀø¡¤á÷¡™øûS|qj¥ŒŒ÷8øÕB}_‰¥‚~¬Sûû5ûRûG¥RØäÅÜØÀ‰5û±}^r‡T‡{÷…û¬÷Ù÷÷÷Oèª¨v^)û ûi"hvª¶üûc¢ÿH€ ÿ € ¤w÷õûÜ÷rì¼Æˆ>xr#X‚€Œ•—˜‹‹  wšwf‡h‡Z¸|¬äÅÖ÷4´óø/ˆÜd„1{b‰{­Œ­ˆ„‹zŒ‰‹ˆˆ~†t€b÷%÷Ê¡z¬jstxhh¢z¤¬›ªŸ-‹›ù›Ùø¿û÷àæù¿ƒ“Š›RØû¡NûhxId‡\‡{÷µ›ExŒ°¨ Ê›Á¨ğĞ÷o÷¢«³–“¦˜›ûQ{¾†‰paû#û2^Ssç`÷¦«¥¹›ûƒ-‹¯øÙ¯…øøøòù!üz]û&†­Ğ¡¹÷-‹÷?üsüï}øÁ÷<xZ$fkû8‹û5øwøïûbûm®à­À®ø4v©áÓÕ×â÷òõcg\bONm¸ØëĞ÷E÷Ÿ†|z|…‹qtš}¤¤¡§ªr½7û(ûû-û!û
ÌjÇ…U5”ƒ•––‹£¡zs‹kTrt“’yzn«~­ƒ£‹¼ÔÏ¶g£_…Š‰‚±Ãë‘ÀÑ£©yù!œû†˜÷’÷ üt}™ù*™ûv•÷s‹÷š“ü|Œ	«
×÷ù
endstream
endobj
11 0 obj
<<
/Flags 98
/Descent -205
/Type/FontDescriptor
/StemH 0
/CapHeight 653
/StemV 76
/FontName/FXYGCU+Times-Italic
/XHeight 683
/Ascent 676
/FontBBox[-169 -217 1010 883]
/ItalicAngle -15.5
/FontFile3 10 0 R
>>
endobj
12 0 obj
<<
/Subtype/Type1
/Type/Font
/FirstChar 32
/LastChar 171
/BaseFont/FXYGCU+Times-Italic
/Name/F0
/Widths[250 0 0 0 0 0 0 0 333 333 0 0 250 333 250 0 500 500 500 500 500 500 500 500 500 500 333 333 0 0 0 0 0 611 611 667 722 611 611 722 722 0 444 667 556 833 667 722 611 0 611 500 556 0 611 0 0 556 556 0 0 0 0 0 0 500 500 444 500 444 278 500 500 278 278 444 278 722 500 500 500 500 389 389 278 500 444 0 444 444 389 0 0 0 0 0 0 0 0 0 0 0 0 500 0 0 0 0 0 444 444 0 0 0 278 0 0 278 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333]
/FontDescriptor 11 0 R
/Encoding 9 0 R
>>
endobj
13 0 obj
<<
/BaseEncoding/MacRomanEncoding
/Type/Encoding
/Differences[32/space 58/colon 65/A/B/C/D/E/F/G/H/I 75/K/L/M/N/O/P 82/R/S/T/U 87/W 89/Y 97/a/b/c/d/e 105/i 108/l 110/n/o 114/r/s 117/u/v/w 121/y 146/iacute 151/oacute 234/Iacute 238/Oacute]
>>
endobj
14 0 obj
<<
/Subtype/Type1C
/Length 4641
/Length1 4641
>>
stream
  HOVTWK+Times-Bold   @ø øøøøû<ûnú|ú;
 ‹‹
 ‹‹  3  /  ˆÄ  è ·ÁÆ003.001Copyright (c) 1985, 1987, 1989, 1990, 1993, 1997, 1998, 1999 Adobe Systems Incorporated.  All Rights Reserved.Times is a trademark of Linotype-Hell AG and/or its subsidiaries.Times BoldTimes  )  0 ' 5 " - . 1 ¶  % * 4 3 & $ ) : 8 6 / B T P D M Ó O J  V Ø C S W F » # , Z X E ( +   X ½u¾*òõUÿcÒ>É0Œ‡Ñ		F	‘	ı
N
…
ÜBøQ¤ˆü$÷x¬ù¬®÷E÷ö÷Eøù&÷ °ûDû&4…ûû?û?…÷â÷&°÷D÷ ¬ûUû5ûûnûf÷)û%÷a÷a÷)÷%÷f÷nû5÷ûUd‹¤÷Ä­÷«­r¤ó÷6÷-¤÷£Ş›ùºˆ´‰IüxMlˆR…r÷ü¤EcÍ÷}÷›B9–¤÷ær<}|Eû†î÷|¶Á÷@¦L#¡£÷]üËœ‹¤øÿ«ÿ  € ÿ € ÷U÷6÷T§ø•¤Asàø£Ğ‡ò†Ÿû4¨‰÷]üìˆû]¨Ÿ÷4òÑü£7s‰B…r÷ùÓ‹¤÷@²øZw”÷ûù<èùE¤‡^{®ó_ûsø¢oğûrü¸m@}iUƒr÷_¤i[±››´§Ó÷u™k«ApjyŠM†r÷Øüˆ÷€é÷‡ğû‡œ‹¤rªù ¤ô÷6pù÷wnû]S8û+Hu“»ølãªŒÑ¤ûñr¸ˆ´‰I°üxNmˆS„prøÖ÷º‹¤ù¤ôµø§÷/ú-¤I”uÛøNá«Ã¤ûû\ülû\ølû‘rÒ†}WüoQ~|=„r÷~¤8y£Ñøe÷üá¦÷øğüŒInˆO…r÷àd‹¤÷ª®÷Ã®r¤ï÷6÷:÷@ì›÷â¤F”xÜ÷N÷Œ¾ŒË¯Û¸–Ò‹®‹÷=ûJš;‹ûÖÜrÀ†ªˆ7üNS}~‚„†‰ŠZƒì÷ŠøÙ¡Œ˜˜­İ¯eûûalû€û™‹¤ù¤÷÷6ø¤TcËøxÏ»Œº¤ûòr¹ˆº‰IüxMd‡U†r÷òQùÎ£š›•§¯l“yx‰qtûû1Ãü$Ó‹¤r®øó­r¤ì÷6÷•÷B¬™÷Ğ÷“÷ ÷0÷L÷.0÷Bû¬ûÅœr²‡·‰NüfwnLl÷‰øÎ“Ÿ‘Ã÷@¢ûi0ûƒ3Kû[‚³û™‹¤ù¤÷÷6ø¤TcËøxÏ»Œº¤ûòr¹ˆº‰IüxMd‡U†r÷ò-x¬ùª®¨w÷÷…÷P©äøxøo÷mmx††|tn\¬;ØûRlûN]‹5÷?9ÎkÌlºs‹H~†(ûèûQ÷ğwnû‹¨› ª¸iê÷LË÷ã÷?Åiœû'ÔÔ7µx¡ÁÌÂ©¿÷
ÇûEÓ‹¤÷´«÷½­r¤÷÷6÷K÷?ì÷¨øìª–ÂÛ´`&ûWuûŠøKûÔ|Œ}û]÷±Áœòª‹÷÷<ûh“EûÖÜrÄ‡ª‰5üN:wˆGƒr÷æ¤I”uÛ÷X¦÷cûÍ÷aœ‹¤rª÷¾­÷«­r¤ó÷6÷6¥÷¤¯›ù¹ˆµ‰IüxMlˆR…wrøİ³÷doû+L%q)Jx—·÷†î¾mû—¥÷æqû|Zp.†÷|¶Â÷Òrû"¢¤÷]üÕÓx»ù	¬ˆw¼÷Eø6¤Øù%÷,.8@m=l<šÓafË…ëÇ÷=²÷-÷&÷ßû	4®¤¸÷~pØr‚vpq>¼1ûfû$û0û_ûO÷û8÷}÷ÙÊŞÔ÷‹¤÷Áº÷ª¤õ÷6÷…÷6ù‹¤V’hÇøxÌ¸¶¤ûèr·ˆ¹‰Iûcû…÷cÍ¹·¤ûårµ‡¶‰JüxPk†V„r÷å¤V‘fÈ÷z÷…ûzNf‡V…r÷èÓ‹¤ù¤÷ª÷6÷÷ùOù8ûprºˆ°‰dpkT„€ûûMû÷|ƒ›{¤‹š§—‘Ğ¤ûãr¾ˆ£`‚÷Kûàû'8s‰F„r÷ï¤E’uŞ÷L÷S÷ËŸ«¨÷ò‘vù.¤ùø÷úiù8ûJr­‰®Šbv‡€ˆûûè‰ ÷á…ƒ£‹—­¨Œ¶¤ûÌr»‰–€˜u®+û	ûÅ‰û÷ı‡–ˆ–‹–°§¯¤ûºrµ…•œ[÷hüî§÷Jøh’÷<üh¦÷\øî—°¡£®Óx¼ù¤í÷3÷Ö·ùQù8ûprá‡—iNûÅK‰û-ûDû$‹÷Ä÷âãªŒÍ¤ûærÃ…¥‰7ûâû ¥h¶eRÌé…·ÇâÁ½µ¸™äÆ÷ÓÍ¢–Â“Óv¤ù¤ó·øC·x›÷w¤A“vÓø$¸øQü²§øá»‘¢Ó”¤ûkrÜ…—jOûÃ‰ûïø?ûgr˜›ˆFÃxünIo„O„û*}ËKÒø«¤÷&û÷÷÷¬ømËˆˆˆŠ‡‹u‹‘÷™é2¶ûûLNLGÁ‹—¿š±²m“‹ ›¢Ÿ¯Õ™fXBtû"`ûc#?Él»£ÑÌÌo‘“aÑ¸°£¬§ûWÄ{}tpig|¯ªâî¨¢û™}­÷Æ÷€¬¤¤tï÷ë`¡²÷è÷Ú÷%uÒƒˆ‡y¬xb¡‹\/HP3û.÷‚‘‹/mvgY´ûsô¦…oû9¤Ÿ•‘“–”Ïn½èËÆê¬÷8û~t‹ñª§¥¯²Ä¹`D û*}ªø=ª¤÷'÷1÷'÷@÷y÷îÕÈœPû.ûƒ6F;‹ó÷ û'ûâû÷÷ä÷÷÷-ôûû4ûûûb}Îøª¤÷!÷÷ø0÷psqnR=NÜ÷ ¸’÷Ùš¥‚mU‹ZÃ“Ç‹ËÓ7°D-û"NûYûá!÷ÚÍ³Ì¹ü‹£ù£Î÷÷“£dª¨øäûRs¼\€ü’s€gcs÷ƒü‹£ø1£Ğ÷÷“£dƒ¡ªøûTs±„š„^ûº[zˆg‚s÷ƒ…øü£š›•§¯l“yx‰qtûû1Ã-‹£øÎg£Õ÷÷÷¸ø¯£Z‹ª£÷Ø÷<ªT6`Os}‰¸ÓûSs³…˜ƒ^ûºZz‡g„s÷…£]ˆ¨¢Ø÷Ÿ”¶¼³ÁŒToû†f}zjˆs÷ü‹£ø1£Ö÷/Ç÷/û&÷è÷“£dƒ¡ªøûTs±„š„^ûº[zˆg‚s÷ƒğûWøù`«i¹¶­¬·¶i®`^jgaûÑ~÷=÷'÷=İ÷=İÒ\¯f»º±¯»¹e²\[gc^÷Ñ\¯e»º±°»¹e±\[gd^-}Ìø£Ì÷÷÷ø­¶^Œ€²÷üû]s­ˆ§ŠTû¯xxrreTŠ¶§÷çûPs´„“cûD­FñÎ¹´¤¨JÄ™Œ÷˜û*}ªø=ª¤÷'÷1÷'÷@÷y÷îÕÈœPû.ûƒ6F;‹ó÷ û'ûâû÷÷ä÷÷÷-ôûû4ûû÷ëø£š›•§¯l“yx‰qtûû1Ã-}«ø%Á÷G£Ó÷÷7÷'œù ¯„‡\üó—ÚÃ¹^»ª‹÷9Ï÷÷÷BğûFgeyz÷—ûV÷VûĞ¡”š°¹â‘ûPû1hXOT~¾§ûb‹£÷Ä÷%5Õs£Ş÷˜÷»£NšÈ¨÷QÔ·¡šÈ«ŠP‹Å½™´¥£|ÁGJ^Olv‰˜ÚûQs©‡£†YûºYu‡k…s÷û*’vøW£÷â÷+øyøaû+s¤Š©‹k~‡|„zCûJ<÷_‚¢‹‹¢ŸŒ¬£ûs¤‡‹—t‘©M¡U÷û¼¥÷4ø Ÿ½™£ûb}Ó÷O°÷4ª¤÷÷8÷®÷­¡°®˜ru‘“m‹WŒlóû1txh_P,uñàˆ÷Áˆ~÷BûBû0-û(û?ñAğÛÄ«èÈ÷x¬ù¬®÷E÷ö÷Eøù&÷ °ûDû&4…ûû?û?…÷â÷&°÷D÷ ¬ûUû5ûûnûf÷)û%÷a÷a÷)÷%÷f÷nû5÷ûU÷
÷£š›•§¯l“yx‰qtûû1Ãœ‹¤r«÷Ë©÷¥©r¤ó÷4÷0÷9û÷@n÷œ÷ë©uÌˆã|û#N~2ûay›¸øŒ¢ŒŒ¥¾vÜ¡PE%uaûûŒü	÷Öm÷gÑíß÷"½7™®µ˜÷¥÷÷0û`SûÉr¹ˆµ‰IüxNk‡S…÷‹¤ù¤÷	÷6ù•¤wŒ}|ûÅø÷<÷@»¼ô‘¤ûµrÓ‡˜…tx‚‚ppûmûn÷já­Â¤ûær¹ˆ´‰IüxNk‡T…r÷å¤V’hÇ÷X¦¤÷Jûw›x“‹~{yˆN‰r÷äû*ûaÄøİ£›÷÷S÷+øtøaû+s¤Š©‹k|†~…zGûTC÷M‚¡€¥‹•£¦Œ¥£ûs¤‡‹—t‘©M¡U÷û»yV„urOi‹†—‹”€¬^O…X}k¦]Ìé Ä÷½÷)ø!½œ¡Ó’vøW£øĞ÷ùWøaûs§ˆŸ‰kuXûp?‰yÙa÷  ¡¥£û~s£ˆ–‹”v‘w•iGû?Y÷i× ¥£™£ûrs¥†„¥J÷(ü
£÷÷ÃïûÃ¢÷/ø%œ·™-}Ãu¢ø
Ã÷G£¤÷(÷7÷|øª¶R‰¨¦øÓûksÂ‡ ŠVûK¥si¯O-(8ûB¼û&ç7ŞÖ§§±¯J|Éœ”Œ÷š¼ûZç€fP];‹÷Åì™åÒÃ¡NŠ÷x¬÷Œ¤ø¬ˆw°÷E÷¿÷0f¤ìù‡÷³ûërĞ‡«‰K"`{m3ûQ…÷Ò÷@³÷,÷%ê÷ßû	4®¤Ú÷~pêr‚vpq>¼1ûlûû6ûYûB÷ûE÷ìâ÷§­»÷İ£É’xù8šûz—÷ ’üu}™ù*™ûv•÷s‹÷š“ü|Œ	·
÷Œ
7’	÷ù
endstream
endobj
15 0 obj
<<
/Flags 262178
/Descent -203
/Type/FontDescriptor
/StemH 0
/CapHeight 676
/StemV 139
/FontName/HOVTWK+Times-Bold
/XHeight 691
/Ascent 676
/FontBBox[-168 -218 1000 935]
/ItalicAngle 0
/FontFile3 14 0 R
>>
endobj
16 0 obj
<<
/Subtype/Type1
/Type/Font
/FirstChar 32
/LastChar 238
/BaseFont/HOVTWK+Times-Bold
/Name/F1
/Widths[250 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 722 667 722 722 667 611 778 778 389 0 778 667 944 722 778 611 0 722 556 667 722 0 1000 0 722 0 0 0 0 0 0 0 500 556 444 556 444 0 0 0 278 0 0 278 0 556 500 0 0 444 389 0 556 500 722 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 278 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 389 0 0 0 778]
/FontDescriptor 15 0 R
/Encoding 13 0 R
>>
endobj
17 0 obj
<<
/BaseEncoding/MacRomanEncoding
/Type/Encoding
/Differences[32/space 37/percent 40/parenleft/parenright 44/comma/hyphen/period/slash/zero/one/two/three/four/five/six/seven/eight/nine/colon/semicolon 64/at/A/B/C/D/E/F/G/H/I 76/L/M/N/O/P 82/R/S/T/U/V 90/Z 97/a/b/c/d/e/f/g/h/i/j/k/l/m/n/o/p/q/r/s/t/u/v/w/x/y/z 135/aacute 142/eacute 146/iacute 150/ntilde/oacute 156/uacute 171/acute 199/guillemotleft/guillemotright 208/endash/emdash 213/quoteright 231/Aacute 238/Oacute]
>>
endobj
18 0 obj
<<
/Subtype/Type1C
/Length 8773
/Length1 8773
>>
stream
  KWTUEF+Times-Roman   @ø øøøøû<ûnú|ú
 ‹‹
 ‹‹  5  1  Ø»  " ·ÂÇ003.001Copyright (c) 1985, 1987, 1989, 1990, 1993, 1997, 1998, 1999 Adobe Systems Incorporated.  All Rights Reserved.Times is a trademark of Linotype-Hell AG and/or its subsidiaries.Times RomanTimes  P  . " $ * «  # 0 & 4    3 / ; » ' %  F D J C E P        Q U B  Ø O S M H Ó N ) T V W Ï × - È  	 
 ! L G ( Y Z I 1 6 5 R } X  [ K  ‰   7 Ş j  x o R   r â?uªúuŞáVÑ2sàQ²W®mú	B	‡	¸	Ó
<
ˆ
é’ßl×<®Lx‡yÖFı@ë$^˜bì:·HÇ=­[Ñı‘ÒEZ¿D˜!¢ş€•ü$÷ƒ‹ù÷·øñùóù*û[ûqüû{øûZxÕ‡ ƒ=ü*û v|?†x÷Bv¡òø#÷ü¶™÷’øÍüU9~|=‡x÷¬Kt”ØøPÚ£‘ÊÓ‹÷Y´ø5wš÷ûùGèùV_}–kÔûøÌwûdüğx_lBtryxz‰{Šx÷Zv\‹µ–™˜¹÷	÷š´+‘}˜j‹{fjŠfx÷“ü~÷•÷÷§÷û§œ}·øò³§÷ù øW‚÷uvjƒj‹†uJ¬2û@û<ûûtû÷A+÷5÷Lá÷ŒylmCDû‹ûûâ÷h÷$·Ë²±´µÅŸ½÷Ó;"¤ûÑ‹ù÷ñ÷½As•ÙøPÛ¤’Ôû½xŞ‡™AüPDz6‰Ó‹÷Y´ø5wš÷ûùGèùV_}–kÔûøÌwûdüğx_lBtryxz‰{Šx÷Zv\‹µ–™˜¹÷	÷š´+‘}˜j‹{fjŠfx÷“ü~÷•÷÷§÷û§ûøb÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(ûÑ v÷VÊ²÷Š²÷•L÷ŠÊœ‹x°÷µ³÷—°x÷ñ÷†ñ:÷®œùİ‡™AüPDz7‰x÷â­÷rŸ÷±ô;»4®¸–ã¡÷÷/ûC™4û¬÷Zûäë«†­u¿{¼j9ûû‚IQy°ø™š™Ÿ•™Œ‹ ¶Òóxûûû‰o,ŠÓ}¯øş¯­÷ø>÷÷ı}÷I÷&÷÷i÷zû7÷û8û8û7ûûzûi÷&û÷I¯û%ä÷p÷x÷Üññ÷:ûxûp%2ûd‹±÷µ´÷”±xîñ÷œ¢¬ÿ € îøé÷=o&_Ymûû)‹Œ´÷Œ÷.‰ŞŠš}—;¢÷|tD€s2û.÷r­—‹ ÷÷¥{2š¤ˆ÷#ü§ŞxÊ†£…<üP>t‚K‡xø°-}¯øù´Òá÷}ğøSù8v€‰†torU­O10Sû(Ë_çV÷'5›iRUcR;ûX÷ºxt©ûh¡›•œ ©¼i‹×÷#Ïëà÷aûâŸ‹÷*É¾ª½ôË19œ¤ü$û*‹šù)w÷iá÷
÷¨š@w–»øìƒûH0}¡Ã‹‹—­‹qvüYAf‰Q‰ü$…÷ 8v÷0² Şû!©•İÍÒŞQ˜trj|`c¯¥’ŒŒŒŒ`’’†‚x{^Iaœ‹÷´¯÷®°xññ÷~÷ìù'bsu¦ûb÷‘¾•÷£÷÷.û9 2û¨ÜxÑ„š‚AüE@‡v:†x÷©;Î÷YÃ÷‚ûÈ÷5ìü[øá¨”’À´÷ˆûû#û*‰7ŠÓ•v–ù÷·ø3·xùWù*ûxÏ†§ƒûûâ‰üøuû?x³›†Y´üMû v|?†x÷Bv¡òø¸øLü¸œø¢÷	«Ê’d‹±øŞ±”øàøÒ÷DBuxJûû•øDøõšü¢wû?¥Î˜—Í÷#÷qüIüõ|øÈ£÷DÓ}¯øş¯­÷ø>÷÷ı}÷I÷&÷÷i÷zû7÷û8û8û7ûûzûi÷&û÷I¯û%ä÷p÷x÷Üññ÷:ûxûp%2ûjùM÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(-‹÷È´÷”±xîñ÷“¢µÿ € îøs÷{÷|t@yw9û%÷r©’¤÷÷¥{2š¤ˆ÷#ü§ŞxÊ†£…<üE9|@‡x÷¬Dw—Ö÷n÷%Ö‰£–7Ó‹°øà°xóñø÷Ø›÷°÷ÆÚ÷X÷÷tû3÷û„û¢¸xØ…–AüPE{?‡Ø÷RøËŸ‹º÷Ãp`»ĞM£:7û·ûŠ‹K[’­û*‹×ø¢Õ÷æáøo÷~dLxˆf‹ûƒ÷<÷D·ºßæ‹õ÷1Ï03-[û+m †¡Á©×æ‹÷
¤/X@`14.ûFûQøûbĞ÷n«÷¯¤Ğ÷eñø,÷8ft`G2I:´÷E÷Ë÷€D¿-;ûNûMû"×9÷÷$Å÷ª•ûÛ÷,ã›²¦ÂÚ•H[’ûbÓø¨¤Øø"÷0Xif`C7F×÷÷'çª°Àym“‘u‘v›r£‹©›¢~ªm ›r^šgû û8û8û2öJÛÜÌ¶÷Áü‹šø–¿w¢w÷!ñÙñ6ßÚ›÷šF†œÍê÷÷‡WxXxWz|˜˜™›ŠPû|=z…MˆÜÉøıx™k¯©¡¡¨§u¢mh|kxû*«øÊ÷8š·wĞß÷wã÷-÷ÖÄË«æ¯$.I{ûûrD˜®7{fôp½÷MÆ÷2åöR÷û?VQt…‰÷Â†[zZ}[~{Œ‘•‹‘·‹vmû*¿ov¼šø§÷8š·w¦á÷wßŸ÷èñgƒdsaICÃ÷)÷Ï¼Ãº¼kG’?÷+û¦Š„…‹†Z‹Ÿ°øË†[zZ}Y~{Œ“•‹‘·‹vmû0¨jm™`û,ûûŸû`÷#w²Õ°°¦NˆÀ¹›»œû*§ø2§¨å÷™å÷‰ø`û9ûûûå$÷÷,Ñ÷î÷%-âûœüNût÷LÕóÂ¿Êç¾ûûû#HeXü•v‹÷÷Œ÷‹wÜ÷¨÷÷ğ ®œ°ªq¥mmrrke­{ ûû ®œ°Xªq¥mmrrk¨e­{ û*˜vøèÕŸøAøUù*ü{_`$œƒ¬¿¨Ì‹÷mûZüèÌ÷hù"ü’vùFw‚÷¼÷³ù8HûyıFÏû*}°øÄÚ÷øÑ÷IøÛ÷X–”‹”±ä‚’€|‚€q‹ûeûûŠ‰‹‰‹Š†ˆ÷ ‡÷E\û4ûASJUpÉ‹Kc‹ngºsÚ÷2÷õ÷ä€¨`¿PÓ-œ;™û*}¥ù¥£ë÷˜ë÷ù÷ûG<‰û„ûû‰÷‚ÜÏ÷÷¥ûLaûwû
ûµût÷L÷Lµ÷t÷÷
a÷wûLû*}§ø¹÷„›­è÷åøRù@û†ƒû>ûJû_ûfñ,÷
÷F¯÷3Ô÷=×!SvjT÷î÷÷F§ûbû²õ©'$û]WL@HÕ÷<Ç•£••£¤¯“­ü$•v‹÷Ñ÷ ÷€ ®œ°`ªq¥mmrrk e­{ û*ûm÷Q«øš‚ÇÖß÷uáÜÖû`‡vI†z÷†C{–Ë÷1k¬§€³÷Ò÷ ÷÷?İ2>]Zov‰Ô…ì[x[z[|{Œ”•‹”®zcÜßˆ±‘Ã§¯÷û6tûB1xjT\¶¢ü¿ø«Ñß÷“øV&÷“‹„fV|ueduuu…‹‹ˆˆŠÀûÁ'´p¾¹º¬¶£~–€~yuk‹X‹Æª÷²ğûbÄ÷†v÷<£°ãFŞ÷(Üô÷³÷mˆl|†‚l~ufnªº­–Ã÷+½÷/û^‚€~vn‹¨¨÷WÇ‹ïû)ìû\Dc{—oª¥¡ ”†š‹šª±¬©º€CNôû7K4i'H¿fÁÂÀ³¬°CµŠ›ªŒ¼µû*}¯øæÇ÷ÒÚeÓĞ÷-÷Ş¤¾¢…{ªËj—Ar@b<.PeÃ‹]{t„oWâ†£÷1÷ã÷"÷6®aàÍ¶¦¶Á´péûH2lûcš‡š§µÙæ‹Õ¯VX/@[0nû*§ø2§¨å÷™å÷‰ø`û9ûûûå$÷÷,Ñ÷î÷%-âûœüNût÷LÕóÂ¿Êç¾ûûû#HeX^ø}÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(û*‹šø˜ÂÛß÷Dß¸ÛåP|~\ˆ|÷hšW}›¬÷­°±ªŸ©ÆgNûe?q†fˆ|÷dšZšº÷y÷D¦]Peh]ZÚ„Ø]z\|^~z–™›ŠLûÑ‹š÷ïíI—‚Ê×ßÈ×ßS{ˆT|÷„šXiĞ˜÷u«·½£È£•h‹®£™¤¬w ieiwD\‰ä†¨ZwYyZ{{”–™›ŠPü‹šøö™·wíß ÷€šQz“Åøé‡VzV}V~{Œ—”Œ˜²‘{^üqTy~P‡û*ûnÄ÷Hv£v÷(¤÷j²§§ÑnŞ<Ç÷XØ¦§Ö í1© ª°º¡‹éˆÕ‰¼‰‹^‹VG_û	‹û‹g³‹ªµ`ÁøDÎ²¢¯á›ûou†AG=qäÚ¹ ÷Ò¹²>{y“vµ šcu“h?+[ûQ­]Æq´ 2<‹~zo¥¦~¶ Xg\b^VÖ_ñå÷:Ã÷§}Õ ¸àû‘mŒ[‹¢Ÿ³´Ÿ‘¯†‹—Ãò²÷ ½‚¢ü‹šø–¿w¢wêßØ›÷šF†œÍè÷÷‡û/T|˜˜™›ŠPû|=z…Mˆåø€÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(÷‹šø˜„¿áß÷Lß÷Lß¼áàHm‰cŠ|÷ršhŒj¼÷®¹ÁĞ¿œdIûmJtˆ^ˆ|÷tšbŒl×÷­¡­¦ÂÓŒPXûgK{‰Y…|÷ošqa’Š¦‹¡÷eÕ}ó#<NOsvµ€lµJUbk^PÖ„Ü]z\|\~z“•™›ŠLÓ‹÷¼·÷°öñ÷Ãñ÷ª=Í÷b÷ÃûW@‡u7‡x÷ª=ÍøPÒ—˜×‘ûªxÕ…™AûVûÃ÷VÒ—˜×‘ûªxÕ…™AüE@‡u7‡û™¡vø[w‘¢¾ÉN˜÷iÑ[˜¥÷Ï÷Î‡÷€™‡ˆ†„‚zlŸ_*`ISAÂfÉh–Åj«yŸs‹kR\{i)xâÀ{Uû0˜–”‘—§µy‹·ËÜµâÇh§Z©™û Ëf¡…¨‹Ÿ¥ ²Â·¸v%¡û*Åiv¶™øœÒß÷Fß<øs½„V‰¡®÷ëû2zÑ‰vcœûj„‚ƒupm}mI‚É™÷Úû&}©‰«‰Oû!Ùs´»²²|¶¶8‰ºœ±™Á™û*’vøUšøçøqøVû|¤Š¡‚tgDû0i+%÷”ˆ“…š‹—¤¡£šûX|ŸŠŸ…šm¯Dëû|£M›`‡”‹’‹”¢–¦÷÷Õ£Æ’›­ûbĞ÷n«÷¯¤Ğ÷eñø,÷8ft`G2I:´÷E÷Ë÷€D¿-;ûNûMû"×9÷÷$Å÷ª•ûÛ÷,ã›²¦ÂÚ•H[’A÷Z÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(û*‹šø˜ÂÓÃÂÛß÷Dß¶ÛåP|~\ˆ|÷hšW}›¬÷­°±ªŸ©ÆgNûe?q†fˆ|÷dšZšº÷y÷D¦]Peh]ZÚ„Ö]z\|^~z–™›ŠL÷Æ÷Àcz}p|v”‘®s—t—u‘v‹HmR_ƒ¨œ‘–¨±—˜†…—¶¢€¨} ª‹ÙÓ­”d‹²øğîñ÷ºù*û®xÊ†£…<üP>t‚K‡xø®»÷BrûRK‡û*8yŒ³ømÚ¤’ÏûbÄ÷†v÷<£°ãFŞ÷(Üô÷³÷mˆl|†‚l~ufnªº­–Ã÷+½÷/û^‚€~vn‹¨¨÷WÇ‹ïû)ìû\Dc{—oª¥¡ ”†š‹šª±¬©º€CNôû7K4i'H¿fÁÂÀ³¬°CµŠ›ªŒ¼µû‘øg÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(û* v÷;ËøQw—³÷„Ùøl÷{%øQ_ûÎüQK÷­û;Ø÷;ñûHËû„÷‚÷èûÑ vù8w»á÷»ù8û///û*û@û¬C¼C±SÍEÅl—›û>÷‹÷oñ÷’ëÙÕÆûÑ vù8w÷[á±ûE÷/çç÷*÷@÷jÓZÓeÃIÑQª{÷>û‹ûo%û’+=AP÷£}²÷
¬k¶÷©·÷ª÷ß÷Ò÷"Î÷<³¾€øĞø#û!~MDaho£Ç÷äÓ»Ş€©˜ta÷ûÚqRWu2ûBû÷÷#÷r÷÷
÷-÷Kôû+û5Zû
:ß€k…£Ÿ“Œ“ŒÌ÷’Fe~£§]‹ûMû>E¾€ûÊ|©ß€Å‘¹¹–Š}£SÌ÷Î÷ñ÷=û$÷ûLûZû;û%ûlû÷ûW÷™ÙÏ§¨Êû*‹šø8š÷C™·wİß’÷~šwŒju“‹´÷I÷ûL—z”‚‹„~~ˆƒx|÷nšpd’XËû-÷V¨¦÷÷§‹À‹šû`}µ“ƒ€‚ƒ€|}ciPTgl‰ø4‡VzV}Z~{Œ“”Œ˜²‘{^üvUƒ‰H€ûÑ‹šø'«÷a§òß÷ÉøVû÷°¿Âº@‹µŸ¢˜¨­_¦SûH‹ûES9kİûÎ>z‚Iˆ|÷˜š/Š¥È÷Î÷Ó}³÷Ê÷®³«÷ø ìd¥øùY÷öû“yÏ†ŸŠ8û6gFtGû/#÷÷I÷‘÷'Êêô÷ ¿(C¦¢ƒ÷guo…j†ƒk]¬&ûhûû;û<û©PÀQ>Ò÷mîø÷÷Å™÷]Ò¥·û*‹š÷©v÷8šœ÷%û%øbû`÷2è÷ÂÔ†—|v‚‡lŠ|÷]šzŒpŒeÅû÷XôŞ÷“˜©©¶Œšû2|œŠ¢Šv€…‚N3x¨bÈ ¤šûc|•¥™…U¯éû$ûû9k]}‰pˆ|÷%šzv‹‰–™ ‘”Ú÷û*ûnß7ñø»š™øaû÷¨øoøVû|¨šy‚~kp=ûrû÷‘ˆ’„›‹˜¦®Œ¢Œšûb}˜‰¥†—r÷ûŠ™l»/|{cûWp~l‹p]‰e…¨q¢k½Ö·Í÷¾÷.ø,š´Ÿ˜û*‹šøÁ÷8š·wÔß÷Nßø{šY”Ô÷[³Š÷ûOZkYh‰÷Â†[zZ}^~{Œ•‹‘·‹vmükB„U„|÷lšZxØ÷…»´²š¨Â¡dHûZ>x†Z†|÷h-‹÷¡³÷½°xïñ÷{÷Ü›ùÔ„–DüEC‹t7…x÷¬>zšÔ÷J‰£Š£ôË´¶œ›·´Ùì÷ûÀûûœ÷ND¬–Œ©·÷&‰û#û,û‹fvwŒxÓ}·øùóñ÷ı·ùUù*û|xÑ‡£z û¢:j~u\nRk=ûB‹÷Ë÷ÔÒ—˜Ú‘û¯x×†™€AûÌO‹ûW÷Œ÷—‹÷PÛ÷™ôœšØ“d‹øíµ´v÷~ñ÷~v8øX7Ïø“Á÷§yû £…÷>üÈ…û>£÷¡¦÷ÁüˆAˆt0‡x÷¸û*ûmœ÷RÈø§‡w£á÷{ßì÷üø=¡dt˜Xû)ûûû+ÖDäÈÑµ©œûNY}t@ˆz÷€™^•y»Üøé‡„ˆBûŞŠk‹{Wxy„z‰|‹2‹dê‹çì÷ÁÔÜêŒDoûÑ vø÷?è÷t÷ø÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(Ó’v÷Àv÷>š ÷ø4÷øÏøV|£†Ÿ‡s…p€r1ûr;÷j|²…–‹¨¤¬šû_|´†–„°û0û[]÷P÷®§¢¢šûH|¤‰“~Ÿ[÷ûêi™’‘–§™÷÷„æû€™g„“‹“•²›÷÷îš°• ’šûÑ vøÌ÷ ‹w÷G²°õøE©•İÍÒŞQ˜trj|`Ğc¯¥’ŒŒŒŒ’’†‚x{^Iaûb‹©ø©ÿ 6€ ÿ € ø6÷y{=…l!‹û÷¡ø)šûïˆû
Á’­Ô÷ûü)|øüûn­øÖ—¾w¢w÷!ñçñ6ßÚ÷^9‹RYgÇ‹`xv|tf¹xº÷´ğ÷	êø]†WwWyW{{š˜™›ŠPÜz÷¾x™k¯©¡¡¨§u¢mh|kx÷K“v˜©÷—­›«÷h¤£©™wÈ×÷r¤Ì×÷q¥Uàù+øû#û!F©Gè÷Ú÷*÷òB’gUà˜k³©gZ6Eû4K‹ÃŸµÁ÷Sì[àa÷ådmkbe7Wy™˜{uà™{}˜]û
*û'&Óh¸÷Ø÷/óà ˆ•‡™…š—‡²Á§š˜¢‰ûñı»uàY÷ädtÂŞÙ÷,Í~{{Ê‘x€zû;û
;÷ò v÷]¼‹ú|÷Zú|¼û*v÷ƒ¶ø§©ç÷„ìÆu÷’›÷&÷R÷h÷;+÷ûû;û û9¹û÷½À°·‰…rTûwû†c÷Æ÷ùyˆ~zvayj!u÷	×İ¢èß÷‹ûWPû*}§ù§Ã×EÕ÷oĞT×ä÷h÷Ì÷9µmAE\aL:]ÌØèæ»²«¥û0û:=Í9÷ä÷:¬÷¿ÎvÅûëØÁ¨Ûµç×MÍû5&U&:³ißAè2Gbl4ØÛø%»«ÀÖØ®UT3Sferg¢2ÄÙÓ•vù"øÉ÷ùMù*ûax±‰®ˆbvza‰…û'üû+÷æt¾y´‹š«Ãûxº‰´0÷Šü¹š÷røÅ©×™™»û*Åiv¶™øœÒß÷Fß<øs½„V‰¡®÷ëû2zÑ‰vcœûj„‚ƒupm}mI‚É™÷Úû&}©‰«‰Oû!Ùs´»²²|¶¶8‰ºœ±™Á™ûšøk÷.ì•‘Ÿ˜‹¢Š§k}„‹ttû'û(û*Ávøwµø2µ÷w‰ÕK•‚SËÂL“‘’˜o³y£u©d·u©¡¨õ÷‹™‹’‰ƒ‹‡‹‹‹KLHPjo÷5p‰ÕK•‚SËÂL“‘’˜o³y£u©d·u©¡¨õ÷‹™‹’‰ƒ‹‡‹‹‹KLHPjoü…÷ 8v÷ò÷‹wÜ÷²”öû!¬—ÚÌÑßP—v€[ˆTf©~«’ŒŒŒŒT’’†‚x{^Iah±øj ®œ°ªq¥mmrrke­{ û*Ávøw·ø2ø^÷rAË”ÃKTÊƒ…†‡„~§cs¡m²_¡mun!û‹}‹„‡“‹‹‹‹——ËÊÎÆ¬§û5¦AË”ÃKTÊƒ…†‡„~§cs¡m²_¡mun!û‹}‹„‡“‹‹‹‹——ËÊÎÆ¬§û* v÷]¼‹øˆ÷Zøˆ¼}™ù*™ûv•÷s‹÷š“ü|Œ}™ù*™ûv•÷s‹÷š“ü|Œ	§
ß÷ù
endstream
endobj
19 0 obj
<<
/Flags 34
/Descent -217
/Type/FontDescriptor
/StemH 0
/CapHeight 662
/StemV 84
/FontName/KWTUEF+Times-Roman
/XHeight 676
/Ascent 683
/FontBBox[-168 -218 1000 898]
/ItalicAngle 0
/FontFile3 18 0 R
>>
endobj
20 0 obj
<<
/Subtype/Type1
/Type/Font
/FirstChar 32
/LastChar 238
/BaseFont/KWTUEF+Times-Roman
/Name/F2
/Widths[250 0 0 0 0 833 0 0 333 333 0 0 250 333 250 278 500 500 500 500 500 500 500 500 500 500 278 278 0 0 0 0 921 722 667 667 722 611 556 722 722 333 0 0 611 889 722 722 556 0 667 556 611 722 722 0 0 0 611 0 0 0 0 0 0 444 500 444 500 444 333 500 500 278 278 500 278 778 500 500 500 500 333 389 278 500 500 722 500 500 444 0 0 0 0 0 0 0 0 0 0 0 0 444 0 0 0 0 0 0 444 0 0 0 278 0 0 0 500 500 0 0 0 0 500 0 0 0 0 0 0 0 0 0 0 0 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 500 500 0 0 0 0 0 0 0 500 1000 0 0 0 333 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 722 0 0 0 0 0 0 722]
/FontDescriptor 19 0 R
/Encoding 17 0 R
>>
endobj
21 0 obj
<<
/Type/Pages
/Kids[22 0 R 23 0 R 24 0 R]
/Count 3
>>
endobj
22 0 obj
<<
/Contents 5 0 R
/Type/Page
/Parent 21 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F1 16 0 R/F2 20 0 R/F0 12 0 R>>/ExtGState<</GS0 1 0 R/GS2 3 0 R/GS3 4 0 R/GS1 2 0 R>>>>
/MediaBox[0 0 501.73199 700.15698]
>>
endobj
23 0 obj
<<
/Contents 6 0 R
/Type/Page
/Parent 21 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F1 16 0 R/F2 20 0 R>>/ExtGState<</GS0 1 0 R/GS2 3 0 R/GS3 4 0 R/GS1 2 0 R>>>>
/MediaBox[0 0 501.73199 700.15698]
>>
endobj
24 0 obj
<<
/Contents 7 0 R
/Type/Page
/Parent 21 0 R
/Resources<</ProcSet[/PDF/Text]/Font<</F1 16 0 R/F0 12 0 R/F2 20 0 R>>/ExtGState<</GS0 1 0 R/GS2 3 0 R/GS3 4 0 R/GS1 2 0 R>>>>
/MediaBox[0 0 501.73199 700.15698]
>>
endobj
25 0 obj
<<
/Type/Catalog
/Pages 21 0 R
/PageLabels 8 0 R
>>
endobj
26 0 obj
<<
/XPressPrivate(%%DocumentProcessColors: Black\n%%EndComments)
/Producer(QuarkXPress(tm) 6.5)
/CreationDate(20071120115332)
/Creator(QuarkXPress(tm) 6.5)
>>
endobj
xref
0 27
0000000000 65535 f 
0000000015 00000 n 
0000000059 00000 n 
0000000111 00000 n 
0000000157 00000 n 
0000000204 00000 n 
0000007777 00000 n 
0000017156 00000 n 
0000021290 00000 n 
0000021335 00000 n 
0000021732 00000 n 
0000030054 00000 n 
0000030277 00000 n 
0000030862 00000 n 
0000031120 00000 n 
0000035844 00000 n 
0000036066 00000 n 
0000036727 00000 n 
0000037218 00000 n 
0000046074 00000 n 
0000046292 00000 n 
0000047032 00000 n 
0000047103 00000 n 
0000047329 00000 n 
0000047545 00000 n 
0000047771 00000 n 
0000047839 00000 n 
trailer
<<
/Size 27
/Root 25 0 R
/Info 26 0 R
/ID[<F5EE80B21F5486CFAF1EE26E227B676B><F5EE80B21F5486CFAF1EE26E227B676B>]
>>
startxref
48014
%%EOF
